Profile data is unavailable for this security.
About the company
Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body’s natural healing process. Its portfolio of products is grouped into three areas. Its Pain Treatments include non-surgical pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions include bone graft substitutes (BGS) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management and tissue debridement in various surgeries. Its Restorative Therapies comprise a bone stimulation system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.
- Revenue in USD (TTM)502.76m
- Net income in USD-122.57m
- Incorporated2015
- Employees970.00
- LocationBioventus Inc4721 EMPEROR BOULEVARD, SUITE 100DURHAM 27703United StatesUSA
- Phone+1 (919) 474-6700
- Fax+1 (302) 655-5049
- Websitehttps://www.bioventus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akoya Biosciences Inc | 96.63m | -63.32m | 199.34m | 330.00 | -- | 3.69 | -- | 2.06 | -1.48 | -1.48 | 2.18 | 1.09 | 0.5423 | 2.49 | 7.23 | 292,827.30 | -35.53 | -- | -44.59 | -- | 58.27 | -- | -65.53 | -- | 2.94 | -10.94 | 0.5882 | -- | 29.09 | -- | 10.36 | -- | -- | -- |
| Utah Medical Products, Inc. | 50.22m | 16.64m | 243.77m | 169.00 | 14.85 | 1.92 | 10.62 | 4.85 | 4.57 | 4.57 | 13.81 | 35.35 | 0.3873 | 2.19 | 11.25 | 297,183.40 | 12.83 | 12.69 | 13.38 | 13.19 | 59.81 | 61.57 | 33.12 | 30.51 | 20.53 | -- | 0.00 | 37.05 | -3.93 | 3.64 | 0.9834 | 1.65 | 9.71 | 1.86 |
| AngioDynamics, Inc. | 324.01m | -192.37m | 251.14m | 815.00 | -- | 1.16 | -- | 0.7751 | -4.78 | -4.78 | 8.10 | 5.41 | 0.7468 | 2.66 | 6.46 | 397,555.80 | -44.34 | -9.12 | -54.02 | -10.17 | 50.17 | 54.23 | -59.37 | -19.48 | 1.62 | -- | 0.00 | -- | 7.13 | 5.30 | -97.54 | -- | 3.55 | -- |
| AxoGen Inc | 159.01m | -21.72m | 253.05m | 426.00 | -- | 2.61 | -- | 1.59 | -0.5070 | -0.5070 | 3.71 | 2.22 | 0.8108 | 1.63 | 6.72 | 373,267.60 | -11.07 | -13.92 | -12.85 | -15.84 | 78.46 | 79.74 | -13.66 | -20.28 | 2.14 | -- | 0.3277 | -- | 14.74 | 13.63 | 24.98 | -- | 17.70 | -- |
| Edap Tms SA (ADR) | 65.00m | -22.78m | 264.92m | 307.00 | -- | 4.33 | -- | 4.08 | -0.616 | -0.616 | 1.76 | 1.65 | 0.6272 | 2.68 | 3.86 | 211,736.50 | -21.98 | -6.62 | -29.54 | -9.22 | 40.40 | 43.23 | -35.05 | -9.59 | 2.30 | -27.44 | 0.1045 | -- | 9.64 | 9.05 | -622.06 | -- | 32.75 | -- |
| Senseonics Holdings Inc | 22.39m | -60.39m | 268.01m | 132.00 | -- | 7.48 | -- | 11.97 | -0.1023 | -0.1023 | 0.0387 | 0.1385 | 0.1418 | 2.40 | 6.41 | 169,621.20 | -38.24 | -73.65 | -45.21 | -106.97 | 13.81 | -40.41 | -269.73 | -649.86 | 7.03 | -- | 0.3593 | -- | 36.62 | 3.43 | -142.49 | -- | -18.76 | -- |
| Sight Sciences Inc | 81.06m | -55.55m | 296.49m | 214.00 | -- | 2.44 | -- | 3.66 | -1.14 | -1.14 | 1.67 | 2.45 | 0.4269 | 1.70 | 5.51 | 378,761.70 | -29.26 | -38.78 | -31.77 | -42.20 | 85.34 | 80.74 | -68.53 | -105.14 | 12.65 | -10.59 | 0.2201 | -- | 13.63 | 60.84 | 35.59 | -- | 6.77 | -- |
| Bioventus Inc | 502.76m | -122.57m | 316.07m | 970.00 | -- | 1.76 | -- | 0.6287 | -1.97 | -2.93 | 8.06 | 2.25 | 0.4552 | 2.14 | 4.10 | 448,889.30 | -14.34 | -- | -18.91 | -- | 62.87 | 70.26 | -31.51 | -9.18 | 0.9443 | 0.3731 | 0.6354 | -- | 18.85 | 11.89 | -919.12 | -- | -- | -- |
| Tactile Systems Technology Inc | 274.42m | 28.52m | 339.17m | 992.00 | 12.02 | 1.74 | 9.68 | 1.24 | 1.19 | 1.19 | 11.90 | 8.20 | 1.02 | 6.02 | 5.60 | 276,636.10 | 10.63 | 0.9015 | 13.23 | 1.09 | 49.95 | 49.10 | 10.39 | 0.8309 | 2.99 | -- | 0.1308 | 0.00 | 11.20 | 13.81 | 259.60 | 33.91 | -23.62 | -- |
| Zynex Inc | 188.68m | 8.17m | 351.23m | 1.10k | 48.65 | 10.76 | 27.77 | 1.86 | 0.2261 | 0.2261 | 5.39 | 1.02 | 1.59 | 2.52 | 6.56 | 171,530.00 | 6.89 | 14.58 | 8.41 | 17.52 | 80.22 | 79.62 | 4.33 | 10.44 | 2.87 | 7.24 | 0.6381 | -- | 16.54 | 42.01 | -42.91 | 0.3741 | 2.19 | -- |
| Pulmonx Corp | 72.99m | -58.73m | 381.13m | 279.00 | -- | 3.42 | -- | 5.22 | -1.54 | -1.54 | 1.91 | 2.87 | 0.399 | 1.14 | 7.81 | 261,627.20 | -32.11 | -26.27 | -35.87 | -28.97 | 74.31 | 71.95 | -80.46 | -93.76 | 6.14 | -- | 0.252 | -- | 27.98 | 27.98 | -3.26 | -- | 20.62 | -- |
| Neuropace Inc | 65.42m | -32.96m | 391.74m | 171.00 | -- | 18.37 | -- | 5.99 | -1.28 | -1.28 | 2.53 | 0.7423 | 0.590 | 1.65 | 6.61 | 382,578.90 | -29.72 | -- | -33.88 | -- | 73.56 | -- | -50.38 | -- | 5.02 | -4.97 | 0.7339 | -- | 43.72 | -- | 30.00 | -- | -- | -- |
| MaxCyte Inc | 41.29m | -37.92m | 393.57m | 143.00 | -- | 1.69 | -- | 9.53 | -0.3675 | -0.3675 | 0.3998 | 2.23 | 0.1488 | 0.4558 | 4.27 | 288,727.30 | -13.67 | -13.18 | -14.54 | -14.33 | 88.51 | 88.79 | -91.85 | -62.96 | 9.97 | -- | 0.00 | -- | -6.72 | 19.89 | -60.89 | -- | 39.13 | -- |
| Nevro Corp | 425.17m | -92.21m | 414.13m | 1.22k | -- | 1.40 | -- | 0.974 | -2.57 | -2.57 | 11.82 | 8.06 | 0.6868 | 1.24 | 5.37 | 349,937.40 | -14.90 | -13.64 | -17.15 | -16.68 | 68.22 | 68.54 | -21.69 | -20.67 | 4.94 | -- | 0.4191 | -- | 4.63 | 1.88 | -3,172.74 | -- | 0.9012 | -- |
| ZimVie Inc | 457.43m | -56.05m | 430.09m | 2.60k | -- | 1.04 | -- | 0.9402 | -2.12 | -14.87 | 17.33 | 15.12 | 0.3213 | 1.07 | 3.91 | 175,935.80 | -3.94 | -- | -4.56 | -- | 63.48 | 65.51 | -12.25 | -8.73 | 2.32 | -0.5562 | 0.5541 | -- | -1.26 | -16.08 | -19.50 | -- | -23.70 | -- |
| Pulse Biosciences Inc | 0.00 | -42.21m | 431.86m | 56.00 | -- | 9.72 | -- | -- | -0.8936 | -0.8936 | 0.00 | 0.8044 | 0.00 | -- | -- | 0.00 | -61.61 | -93.21 | -67.89 | -104.99 | -- | -- | -- | -12,332.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.85 | -- | -15.20 | -- |
Data as of May 06 2024. Currency figures normalised to Bioventus Inc's reporting currency: US Dollar USD
26.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Juniper Investment Co. LLCas of 31 Dec 2023 | 6.83m | 10.78% |
| Nantahala Capital Management LLCas of 31 Dec 2023 | 5.98m | 9.43% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.20m | 1.90% |
| Kent Lake Capital LLCas of 31 Dec 2023 | 532.88k | 0.84% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 491.32k | 0.78% |
| Geode Capital Management LLCas of 31 Dec 2023 | 407.44k | 0.64% |
| Bridgeway Capital Management LLCas of 31 Dec 2023 | 363.80k | 0.57% |
| Jacobs Levy Equity Management, Inc.as of 31 Dec 2023 | 328.83k | 0.52% |
| Susquehanna Financial Group LLLPas of 31 Dec 2023 | 255.73k | 0.40% |
| Millennium Management LLCas of 31 Dec 2023 | 235.48k | 0.37% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
